Activation of the thromboxane A2 receptor by 8-isoprostane inhibits the pro-angiogenic effect of vascular endothelial growth factor in scleroderma

Journal of Investigative Dermatology

Volumn 135, Issue 12, 2015, Pages 3153-3162

  Tsou, Pei Suen ^a   Amin, M Asif ^a   Campbell, Phillip L ^a   Zakhem, George ^a   Balogh, Beatrix ^a   Edhayan, Gautam ^a   Ohara, Ray A ^a   Schiopu, Elena ^a   Khanna, Dinesh ^a   Koch, Alisa E ^a,b   Fox, David A ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

8 ISOPROSTANE; ALPHA TOCOPHEROL; FOCAL ADHESION KINASE; RHO KINASE; RHO KINASE 1; RHO KINASE 2; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SUPEROXIDE; THROMBOXANE A2 RECEPTOR; UNCLASSIFIED DRUG; VASCULOTROPIN; 8-EPI-PROSTAGLANDIN F2ALPHA; COLLAGEN; DRUG COMBINATION; LAMININ; MATRIGEL; PROSTAGLANDIN F2 ALPHA; PROTEOGLYCAN; VASCULOTROPIN A;

ADULT; ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CHEMOTAXIS; CONTROLLED STUDY; DIFFUSE SCLERODERMA; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; INTERSTITIAL LUNG DISEASE; LIMITED SCLERODERMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; DRUG COMBINATION; DRUG EFFECTS; METABOLISM; PATHOPHYSIOLOGY; PHOSPHORYLATION; PHYSIOLOGY; SYSTEMIC SCLEROSIS;

ADULT; COLLAGEN; DINOPROST; DRUG COMBINATIONS; ENDOTHELIAL CELLS; FEMALE; FOCAL ADHESION PROTEIN-TYROSINE KINASES; HUMANS; LAMININ; MALE; MIDDLE AGED; NEOVASCULARIZATION, PHYSIOLOGIC; OXIDATIVE STRESS; PHOSPHORYLATION; PROTEOGLYCANS; RECEPTORS, THROMBOXANE A2, PROSTAGLANDIN H2; RHO-ASSOCIATED KINASES; SCLERODERMA, SYSTEMIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84948719160     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2015.323     Document Type: Article

References (42)

1. Ashton AW, Cheng Y, Helisch A, et al. (2004). Thromboxane A2 receptor agonists antagonize the proangiogenic effects of fibroblast growth factor-2: role of receptor internalization, thrombospondin-1, and alpha(v)beta3. Circ Res 94: 735-42
2. Ashton AW, Ware JA. (2004). Thromboxane A2 receptor signaling inhibits vascular endothelial growth factor-induced endothelial cell differentiation and migration. Circ Res 95: 372-9
3. Ashton AW, Yokota R, John G, et al. (1999). Inhibition of endothelial cell migration, intercellular communication, and vascular tube formation by thromboxane A(2). J Biol Chem 274: 35562-70
4. Avouac J, Borderie D, Ekindjian OG, et al. (2010). High DNA oxidative damage in systemic sclerosis. J Rheumatol 37: 2540-7
5. Benndorf RA, Schwedhelm E, Gnann A, et al. (2008). Isoprostanes inhibit vascular endothelial growth factor-induced endothelial cell migration, tube formation, and cardiac vessel sprouting in vitro, as well as angiogenesis in vivo via activation of the thromboxane A(2) receptor: a potential link between oxidative stress and impaired angiogenesis. Circ Res 103: 1037-46
6. Bruckdorfer KR, Hillary JB, Bunce T, et al. (1995). Increased susceptibility to oxidation of low-density lipoproteins isolated from patients with systemic sclerosis. Arthritis Rheum 38: 1060-7
7. Comporti M, Signorini C, Arezzini B, et al. (2008). F2-isoprostanes are not just markers of oxidative stress. Free Radic Biol Med 44: 247-56
8. Daniel TO, Liu H, Morrow JD, et al. (1999). Thromboxane A2 is a mediator of cyclooxygenase-2-dependent endothelial migration and angiogenesis. Cancer Res 59: 4574-7
9. Davi G, Alessandrini P, Mezzetti A, et al. (1997). In vivo formation of 8-Epiprostaglandin F2 alpha is increased in hypercholesterolemia. Arterioscler Thromb Vasc Biol 17: 3230-5
10. Davies CA, Jeziorska M, Freemont AJ, et al. (2006). The differential expression of VEGF, VEGFR-2, and GLUT-1 proteins in disease subtypes of systemic sclerosis. Hum Pathol 37: 190-7
11. Distler O, Del Rosso A, Giacomelli R, et al. (2002). Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers. Arthritis Res 4: R11
12. Distler O, Distler JH, Scheid A, et al. (2004). Uncontrolled expression of vascular endothelial growth factor and its receptors leads to insufficient skin angiogenesis in patients with systemic sclerosis. Circ Res 95: 109-16
13. Gao Y, Yokota R, Tang S, et al. (2000). Reversal of angiogenesis in vitro, induction of apoptosis, and inhibition of AKT phosphorylation in endothelial cells by thromboxane A(2). Circ Res 87: 739-45
14. Giusti B, Margheri F, Rossi L, et al. (2013). Desmoglein-2-integrin Beta-8 interaction regulates actin assembly in endothelial cells: deregulation in systemic sclerosis. PLoS One 8: e68117
15. Giusti B, Serrati S, Margheri F, et al. (2005). The antiangiogenic tissue kallikrein pattern of endothelial cells in systemic sclerosis. Arthritis Rheum 52: 3618-28
16. Hou X, Roberts LJ 2nd, Gobeil F Jr, et al. (2004). Isomer-specific contractile effects of a series of synthetic f2-isoprostanes on retinal and cerebral microvasculature. Free Radic Biol Med 36: 163-72
17. Hummers LK, Hall A, Wigley FM, et al. (2009). Abnormalities in the regulators of angiogenesis in patients with scleroderma. J Rheumatol 36: 576-82
18. Ishizuka T, Kawakami M, Hidaka T, et al. (1998). Stimulation with thromboxane A2 (TXA2) receptor agonist enhances ICAM-1, VCAM-1 or ELAM-1 expression by human vascular endothelial cells. Clin Exp Immunol 112: 464-70
19. Kumar A, Kingdon E, Norman J. (2005). The isoprostane 8-iso-PGF2alpha suppresses monocyte adhesion to human microvascular endothelial cells via two independent mechanisms. FASEB J 19: 443-5
20. Kuryliszyn-Moskal A, Klimiuk PA, Sierakowski S. (2005). Soluble adhesion molecules (sVCAM-1, sE-selectin), vascular endothelial growth factor (VEGF) and endothelin-1 in patients with systemic sclerosis: relationship to organ systemic involvement. Clin Rheumatol 24: 111-6
21. Lamalice L, Le Boeuf F, Huot J. (2007). Endothelial cell migration during angiogenesis. Circ Res 100: 782-94
22. LeRoy EC. (1974). Increased collagen synthesis by scleroderma skin fibroblasts in vitro: a possible defect in the regulation or activation of the scleroderma fibroblast. J Clin Invest 54: 880-9
23. Mackiewicz Z, Sukura A, Povilenaite D, et al. (2002). Increased but imbalanced expression of VEGF and its receptors has no positive effect on angiogenesis in systemic sclerosis skin. Clin Exp Rheumatol 20: 641-6
24. Manetti M, Guiducci S, Romano E, et al. (2011). Overexpression of VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, leads to insufficient angiogenesis in patients with systemic sclerosis. Circ Res 109: e14-26
25. Montuschi P, Ciabattoni G, Paredi P, et al. (1998) 8-Isoprostane as a biomarker of oxidative stress in interstitial lung diseases. Am J Resp Crit Care Med 158: 1524-7
26. Morrow JD. (2000). The isoprostanes: their quantification as an index of oxidant stress status in vivo. Drug Metab Rev 32: 377-85
27. Nie D, Lamberti M, Zacharek A, et al. (2000). Thromboxane A(2) regulation of endothelial cell migration, angiogenesis, and tumor metastasis. Biochem Biophys Res Commun 267: 245-51
28. Nobes CD, Hall A. (1999). Rho GTPases control polarity, protrusion, and adhesion during cell movement. J Cell Biol 144: 1235-44
29. Ogawa F, Shimizu K, Muroi E, et al. (2006). Serum levels of 8-isoprostane, a marker of oxidative stress, are elevated in patients with systemic sclerosis. Rheumatology 45: 815-8
30. Rabquer BJ, Tsou PS, Hou Y, et al. (2011). Dysregulated expression of MIG/CXCL9, IP-10/CXCL10 and CXCL16 and their receptors in systemic sclerosis. Arthritis Res Ther 13: R18
31. Roberts LJ 2nd, Milne GL. (2009). Isoprostanes. J Lipid Res 50: S219-23
32. Sambo P, Baroni SS, Luchetti M, et al. (2001). Oxidative stress in scleroderma: maintenance of scleroderma fibroblast phenotype by the constitutive upregulation of reactive oxygen species generation through the NADPH oxidase complex pathway. Arthritis Rheum 44: 2653-64
33. Scholz H, Yndestad A, Damas JK, et al. (2003) 8-isoprostane increases expression of interleukin-8 in human macrophages through activation of mitogen-Activated protein kinases. Cardiovasc Res 59: 945-54
34. Servettaz A, Guilpain P, Goulvestre C, et al. (2007). Radical oxygen species production induced by advanced oxidation protein products predicts clinical evolution and response to treatment in systemic sclerosis. Ann Rheum Dis 66: 1202-9
35. Stein CM, Tanner SB, Awad JA, et al. (1996). Evidence of free radical-mediated injury (isoprostane overproduction) in scleroderma. Arthritis Rheum 39: 1146-50
36. Svegliati S, Cancello R, Sambo P, et al. (2005). Platelet-derived growth factor and reactive oxygen species (ROS) regulate Ras protein levels in primary human fibroblasts via ERK1/2. Amplification of ROS and Ras in systemic sclerosis fibroblasts. J Biol Chem 280: 36474-82
37. Tkach V, Bock E, Berezin V. (2005). The role of RhoA in the regulation of cell morphology and motility. Cell Motil Cytoskeleton 61: 21-33
38. Tsou P, Rabquer BJ, Balogh B, et al. (2012). Primary human scleroderma dermal endothelial cells exhibit defective angiogenesis. Arthritis Rheum 64: S645
39. Tsou PS, Balogh B, Pinney AJ, et al. (2014). Lipoic acid plays a role in scleroderma: insights obtained from scleroderma dermal fibroblasts. Arthritis Res Ther 16: 411
40. Tsou PS, Talia NN, Pinney AJ, et al. (2012). Effect of oxidative stress on protein tyrosine phosphatase 1B in scleroderma dermal fibroblasts. Arthritis Rheum 64: 1978-89
41. Tufvesson E, Bozovic G, Hesselstrand R, et al. (2010). Increased cysteinylleukotrienes and 8-isoprostane in exhaled breath condensate from systemic sclerosis patients. Rheumatology 49: 2322-6
42. Wojciak-Stothard B, Torondel B, Tsang LY, et al. (2007). The ADMA/DDAH pathway is a critical regulator of endothelial cell motility. J Cell Sci 120: 929-42